Across TCGA pan-cancer cohorts, OR1J2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated OR1J2 data layer compared with 17 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher OR1J2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR1J2 expression acts as an unfavorable survival marker.

HNSC, UCEC, and SARC are the cancer types where OR1J2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.173	0.687	.002	33	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SARC	DFS	Median	All	0.158	0.516	.047	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: OR1J2 tumor-vs-normal RNA expression · all OR1J2 data types